Efficacy and safety of Methylnaltrexone Bromide treatment for opioid induced constipation in patients with non small cell lung cancer

Trial Profile

Efficacy and safety of Methylnaltrexone Bromide treatment for opioid induced constipation in patients with non small cell lung cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Oct 2016

At a glance

  • Drugs Methylnaltrexone bromide (Primary)
  • Indications Constipation
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 27 Oct 2016 New trial record
    • 01 Oct 2016 Results published in the Journal of Thoracic Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top